دورية أكاديمية
Dramatic Response to Concurrent Anti-PD-1 Therapy and Radiation in Resistant Tumors with Sarcomatoid Differentiation.
| العنوان: | Dramatic Response to Concurrent Anti-PD-1 Therapy and Radiation in Resistant Tumors with Sarcomatoid Differentiation. |
|---|---|
| المؤلفون: | Tolay S; Department of Hematology and Oncology, Lehigh Valley Health Network, Allentown, Pennsylvania, USA drsameertolay@gmail.com., Nair R; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., McIntosh AF; Department of Radiation Oncology, Lehigh Valley Health Network, Allentown, Pennsylvania, USA., Sopka DM; Department of Radiation Oncology, Lehigh Valley Health Network, Allentown, Pennsylvania, USA., Nair SG; Department of Hematology and Oncology, Lehigh Valley Health Network, Allentown, Pennsylvania, USA. |
| المصدر: | The oncologist [Oncologist] 2019 Jan; Vol. 24 (1), pp. e49-e52. Date of Electronic Publication: 2018 Aug 13. |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2022- : Oxford : Oxford University Press Original Publication: Dayton, Ohio : AlphaMed Press, c1996- |
| مواضيع طبية MeSH: | Antibodies, Monoclonal, Humanized/*therapeutic use , Sarcoma/*drug therapy , Sarcoma/*radiotherapy, Aged ; Antibodies, Monoclonal, Humanized/pharmacology ; Cell Differentiation ; Humans ; Male ; Sarcoma/pathology |
| مستخلص: | A substantial fraction of patients demonstrate resistance to immune checkpoint inhibitors, which limits their use. Use of radiation concurrently with checkpoint inhibitors has been shown to boost immune responsiveness, resulting in significant tumor regression in patients with metastatic melanoma. However, it is unknown whether radiation could play a role in reversing the inherent resistance to checkpoint inhibition in certain tumor types. Most trials testing this concurrent approach exclude such modestly responsive tumors and pursue checkpoint inhibition using anti-cytotoxic T-lymphocyte-associated protein 4 antibody (anti-CTLA-4, ipilimumab). The efficacy of anti-programmed-death-1 (anti-PD-1) therapy when used concurrently with radiation is less known but remains an attractive option due to less autoimmune toxicity compared with CTLA-4 inhibition. In this first reported experience, we have safely and effectively combined anti-PD-1 therapy (nivolumab) concurrently with radiation to treat two patients with relapsed sarcomatoid renal carcinoma and heavily pretreated pleomorphic sarcoma. Both patients experienced a dramatic response that was durable. Competing Interests: Disclosures of potential conflicts of interest may be found at the end of this article. (© AlphaMed Press 2018.) |
| References: | J Immunother Cancer. 2016 Sep 20;4:51. (PMID: 27660705) Ther Adv Med Oncol. 2017 Aug;9(8):533-550. (PMID: 28794805) Vaccine. 2015 Dec 16;33(51):7415-7422. (PMID: 26148880) Cancer Immunol Res. 2015 Dec;3(12):1303-7. (PMID: 26307625) J Clin Oncol. 2018 Jun 1;36(16):1611-1618. (PMID: 29437535) N Engl J Med. 2012 Mar 8;366(10):925-31. (PMID: 22397654) N Engl J Med. 2017 Oct 5;377(14):1345-1356. (PMID: 28889792) Nature. 2015 Apr 16;520(7547):373-7. (PMID: 25754329) Lung Cancer. 2016 Aug;98:51-58. (PMID: 27393506) J Clin Oncol. 2016 Mar 10;34(8):833-42. (PMID: 26755520) |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) |
| تواريخ الأحداث: | Date Created: 20180815 Date Completed: 20200324 Latest Revision: 20200324 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC6324640 |
| DOI: | 10.1634/theoncologist.2018-0205 |
| PMID: | 30104290 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1549-490X |
|---|---|
| DOI: | 10.1634/theoncologist.2018-0205 |